Pharma Journalist 7879 posts 0 comments

The toolbox of precision genome editing and delivery techniques continue to grow in 2024, enabling the community to make safer and more precise edits to a wider variety of disease…
Read More...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise…
Read More...

SELLAS Life Sciences Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Galinpepimut-S (GPS), an…
Read More...

Firefly Neuroscience, Inc. an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental…
Read More...

Viatris Inc. announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. for sotagliflozin in all markets outside of the United States and Europe.…
Read More...

AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with Radiopharm Ventures…
Read More...

Exelixis, Inc. and Merck, known as MSD outside of the United States and Canada, announced that the companies have entered into a clinical development collaboration to evaluate the…
Read More...

In December, 120 senior figures from industry and academia will be uniting at the foremost gene editing drug development meeting, the 5th Genome Editing Therapeutics Summit (formerly…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with unresectable,…
Read More...

UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing…
Read More...